The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Month: May 2023

Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
Editor's Choice

Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks

MAY 25, 2023
Vaginal probiotics quietly making progress in drug reclassification in the EU
Biotics and Supplements

Vaginal probiotics quietly making progress in drug reclassification in the EU

MAY 23, 2023
BiomeSense Closes Oversubscribed $3 Million Funding Round
Finance

BiomeSense Closes Oversubscribed $3 Million Funding Round

MAY 22, 2023
NIH launches largest precision nutrition research effort of its kind
Pharma & Human Health

NIH launches largest precision nutrition research effort of its kind

MAY 19, 2023
Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study finds
Gastrointestinal

Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study finds

MAY 17, 2023
Exhaled breath can reveal crucial insight into the microbiome
Pharma & Human Health

Exhaled breath can reveal crucial insight into the microbiome

MAY 12, 2023
DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
Editor's Choice

DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device

MAY 10, 2023
Solarea Bio Announces First Close of Series B Financing Round
Finance

Solarea Bio Announces First Close of Series B Financing Round

MAY 9, 2023
SNIPR Biome’s data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
Finance

SNIPR Biome’s data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

MAY 8, 2023
New discovery stops bacterial virus contamination
Infectious Disease & AMR

New discovery stops bacterial virus contamination

MAY 3, 2023
Recipharm will manufacture VOWST on behalf of Seres Therapeutics
Finance

Recipharm will manufacture VOWST on behalf of Seres Therapeutics

MAY 2, 2023